Characteristics of second primary malignancies following bispecific antibodies therapy.

For other BsAbs types (including EGFR-MET, gp100-HLA-CD3, GPRC5D-CD3), non-Hodgkin’s lymphoma and myeloid leukemias were also identified, although these findings did not reach statistical significance ( figure 3D–E ; Online supplemental figure S1A-B ).

also in 111,027 other papers

Remarkably, the frequency of hematological malignancies declined over time, whereas solid tumors showed an increasing trend ( figure 2B ).

also in 63,971 other papers